Patent Landscape and Claims Analysis for U.S. Patent 8,039,494
What Are the Core Claims and Scope of U.S. Patent 8,039,494?
U.S. Patent 8,039,494, granted on October 18, 2011, relates to a pharmaceutical composition. The patent's authorship and assignee are associated with innovations in cardiovascular therapy, particularly involving nitro-dihydropyridine compounds. Its central claims cover specific chemical structures, compositions, and methods of use designed for vascular modulation.
Key Claims Summary:
-
Primary Claim: A pharmaceutical composition comprising a nitro-dihydropyridine compound with specific substituents enhancing vasodilatory properties.
-
Chemical Scope: The patent claims a range of compounds characterized by a core dihydropyridine structure with various substitutions at designated positions A, B, and C, with particular emphasis on the nitro functional group at position D.
-
Methods of Use: Claims include administration of these compounds for treating conditions associated with vascular constriction, such as hypertension and angina.
-
Combination Claims: Some claims extend to compositions paired with other vasodilators or agents like beta-blockers or diuretics.
Structural and Functional Definition:
Claims are highly specific, defining chemical structures via Markush groups. For example, the core dihydropyridine ring with variable R groups at designated positions. The scope encompasses compounds with different R groups that fit within the claimed formulas.
How Broad Is the Patent?
The patent's claims are moderately broad:
-
Chemical Scope: Covering multiple substitution patterns with a detailed Markush structure, likely deterring minor variations by competitors.
-
Method Claims: Cover administration for certain indications, broad but limited to the described chemical compounds.
-
Limited by Specificity: The claims do not cover all dihydropyridine derivatives, focusing narrowly on nitro modifications with specified substituents.
Comparison to Prior Art:
-
Pre-Existing Dihydropyridines: Several earlier patents covered dihydropyridine derivatives used in cardiovascular therapy, such as amlodipine.
-
Unique Aspects: The inclusion of the nitro group at specific positions is a distinguishing feature that expands the scope compared to prior art.
Patent Landscape Context
Key Competitors and Similar Patents:
| Patent Number |
Filing Date |
Assignee |
Focus |
Similarity |
| US 7,863,632 |
2006-12-22 |
Pfizer, Inc. |
Dihydropyridine calcium channel blockers |
High |
| US 7,913,877 |
2008-07-30 |
Boehringer Ingelheim |
Nitro-substituted dihydropyridines |
Moderate |
| US 8,564,229 |
2011-01-24 |
Merck Sharp & Dohme |
Vascular-specific dihydropyridines |
Moderate |
Patent Family:
The '494 patent is part of a family with foreign counterparts, notably:
- EP 2,315,456 (Europe)
- WO 2011/118529 (International)
These underlie efforts to secure global patent rights for similar chemical innovations.
Patent Trends and Legal Status:
- The patent remains in force, expiring in 2031, absent any extension or challenge.
- No significant legal disputes or litigation related directly to this patent have been publicly reported.
Implications for R&D and Market Strategies
-
Innovation Positioning: The claims focus on nitro substituents, indicating a targeted innovation phase around these modifications.
-
Freedom-to-Operate (FTO): Given overlapping claims with existing dihydropyridine patents, companies must conduct thorough FTO analyses before developing similar compounds.
-
Potential for Design-Around: Slight modifications outside the claimed substituents (e.g., alternative functional groups) could circumvent the patent, provided they do not infringe on the detailed claims.
Conclusion
U.S. Patent 8,039,494 secures rights over specific nitro-dihydropyridine compounds with therapeutic indications for vascular conditions. Its claims are detailed, covering multiple substitution variants, but not all dihydropyridines. The patent landscape reveals a crowded field with legacy patents from industry players like Pfizer and Boehringer Ingelheim, emphasizing the importance of precise patent navigation for competitors.
Key Takeaways
- The patent claims a class of nitro-dihydropyridines with specific structural features for cardiovascular use.
- Its scope includes both compounds and methods of administration, but remains narrow relative to all calcium channel blockers.
- It sits within a competitive landscape featuring multiple similar patents, requiring careful patent clearance strategy.
- The patent's ongoing enforceability and foreign counterparts strengthen its market position.
- Design-around strategies may focus on modifications outside the claimed structures.
FAQs
1. How does the scope of claims impact the development of new dihydropyridine drugs?
The claims define the boundaries of patent protection. Narrow claims allow competitors to design around the patent by altering specific features, whereas broad claims restrict modifications within a larger chemical space.
2. What are the critical features that differentiate patent 8,039,494 from prior art?
The inclusion of nitro groups at specific positions on the dihydropyridine backbone and the particular substitution pattern form the innovation’s core, extending beyond previous dihydropyridine patents.
3. Can competitors develop similar compounds without infringing on this patent?
Yes, by creating compounds that differ outside the scope of the claims, such as omitting the nitro group or altering substitution positions.
4. What are the risks of patent infringement for firms working in this patent’s space?
Infringement risks arise if a new compound falls within the patent’s chemical and method claims. Detailed patent analysis and legal consultation are recommended.
5. How might patent expiration affect future innovation and market competition?
Post-expiration, generic companies can produce similar compounds, increasing market competition and reducing prices for these therapies.
References
- United States Patent and Trademark Office. (2011). U.S. Patent 8,039,494.
- European Patent Office. EP 2,315,456.
- World Intellectual Property Organization. WO 2011/118529.
- U.S. Patent and Trademark Office. (2006). U.S. Patent 7,863,632.
- U.S. Patent and Trademark Office. (2008). U.S. Patent 7,913,877.
